Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.

PPMI Enrollment Status

Genetic Cohort Participants
Enrollment Goal: 600

Genetic Registry Participants
Enrollment Goal: ~600

De Novo PD Participants
Enrollment: 424

Control Participants
Enrollment: 196

Subjects with SWEDD
Enrollment: 64

Prodromal Participants
Enrollment: 65

Last Update: November 1 2018


More about study cohorts >

A Landmark Study of Parkinson’s Disease

The Parkinson’s Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.


Interview on RNA in PPMI with Dr. Van Keuren-Jensen

Today, we will be asking Dr. Van-Keuren Jensen a few questions about RNA and hearing her insight as to why this vital element is something, we are focusing on in the Parkinson’s Progression Markers Initiative (PPMI). Dr. Van Keuren-Jensen received her Ph.D. from Cold Spring Harbor Laboratory in New York, where she studied the role […]

Recent Findings in PPMI

by Krishna Knabe The Michael J. Fox Foundation A group of authors led by PPMI’s principal investigator, Dr. Kenneth Marek, published baseline data from the study in the Annals of Clinical and Translational Neurology. The paper includes detailed biomarker signatures on the initial volunteer groups, which include patients with Parkinson’s disease, healthy controls and those who […]

PPMI Study Enters a New Phase

by Krishna Knabe The Michael J. Fox Foundation The Parkinson’s Progression Markers Initiative (PPMI) has reached an important milestone: the study completed enrollment. We have now met the ambitious goal we set back in 2010 of enrolling 1,400 participants, including 600 with rare genetic mutations. PPMI is The Michael J. Fox Foundation’s landmark observational clinical […]

PPMI Data Available: RNA Seq

by Bradford Casey, Ph.D. The Michael J. Fox Foundation The Parkinson’s Progression Markers Initiative (PPMI) includes a broad and comprehensive panel of measurements designed to improve our understanding of Parkinson’s disease (PD). One approach is analysis of the genome, the full complement of DNA present within the cells of the body. DNA is often considered […]

PPMI Study Update Call – 6/14/18

PPMI Study Update Call Cerebrospinal Fluid Analysis Thursday, June 14 12-1 pm Eastern Time Brit Mollenhauer, MD Attending Neurologist, Head of Clinical Research PPMI Steering Committee Member Paracelsus-Elena Klinik Doug Galasko, MD Professor of Neurology PPMI Steering Committee Member University of California San Diego   PPMI participants are encouraged to call in to the next […]

Learn More